Olema Pharmaceuticals inc (NAS:OLMA)

$ 6.15 -0.17 (-2.69%) Market Cap: 466.46 Mil Enterprise Value: 253.39 Mil PE Ratio: 0 PB Ratio: 1.82 GF Score: 38/100

Olema Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Olema Pharmaceuticals Inc Palazestrant Phase 2 Monotherapy Clinical Update Presentation Transcript
Oct 23, 2023
Olema Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 27, 2023
Olema Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 11, 2023
Olema Pharmaceuticals Inc at Canaccord Genuity Growth Conference Transcript
Aug 09, 2023
Olema Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Olema Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 15, 2023
G1 Therapeutics Inc, Molecular Templates Inc, Olema Pharmaceuticals Inc and Puma Biotechnology Inc at Cowen Health Care Conference- Panel Transcript
Mar 07, 2023
Olema Pharmaceuticals Inc at Citi Virtual Oncology Leadership Summit Transcript
Feb 23, 2023
Olema Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Olema Pharmaceuticals Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Nov 29, 2022
Olema Pharmaceuticals Inc at Jefferies London Healthcare Conference Transcript
Nov 16, 2022
Olema Pharmaceuticals Inc at Credit Suisse Healthcare Conference Transcript
Nov 09, 2022
Olema Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2022
Olema Pharmaceuticals Inc at Canaccord Genuity Horizons in Oncology Conference (Virtual) Transcript
Apr 14, 2022
Olema Pharmaceuticals Inc to Review the Phase 1 Clinical Data for OP-1250 Transcript
Nov 30, 2021
Olema Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 13, 2021

Olema Pharmaceuticals Inc at Canaccord Genuity Horizons in Oncology Conference (Virtual) Transcript

Apr 14, 2022 / 03:30PM GMT

Release Date Price: $3.08 (-5.52%)

Transcript

Arlinda Lee

Canaccord Genuity LLC - Analyst

Good morning. My name is Arlinda Lee and I'm a senior analyst on Canaccord's biotech team. I'm pleased Olema's President and Chief Executive Officer, Sean Bohen, is joining us today for a fireside chat to talk about Olema's dual SERD CERAN OP-1250 and its clinical development. Sean, welcome.

Sean Bohen

Olema Pharmaceuticals, Inc. - President and CEO

Thank you, Arlinda, and thank you for having me.

Questions & Answers

Arlinda Lee

Canaccord Genuity LLC - Analyst

Great. Let's start talking about Olema's 1250. It's currently in monotherapy dose escalation -- dose expansion at the 60 milligram and 120 milligram doses. How do you -- what are the criteria that you're going to use to select the recommended Phase 2 dose and when do you expect to do that?

Sean Bohen

Olema Pharmaceuticals, Inc. - President and CEO

Yeah. So the criteria mainly will be an expansion of tolerability and an expansion of our information with

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.